X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1584) 1584
oncology (1496) 1496
vinorelbine (1130) 1130
female (1095) 1095
aged (1033) 1033
chemotherapy (1015) 1015
lung neoplasms - drug therapy (1011) 1011
male (968) 968
carcinoma, non-small-cell lung - drug therapy (960) 960
middle aged (916) 916
index medicus (868) 868
antineoplastic combined chemotherapy protocols - therapeutic use (810) 810
cisplatin (717) 717
adult (706) 706
vinorelbine plus cisplatin (694) 694
lung neoplasms - pathology (667) 667
treatment outcome (583) 583
carcinoma, non-small-cell lung - pathology (567) 567
vinblastine - analogs & derivatives (553) 553
cancer (522) 522
gemcitabine (521) 521
neoplasm staging (501) 501
respiratory system (468) 468
vinblastine - administration & dosage (457) 457
non-small cell lung cancer (417) 417
lung cancer (410) 410
lung cancer, non-small cell (409) 409
cisplatin - administration & dosage (405) 405
lung neoplasms - mortality (385) 385
docetaxel (380) 380
carboplatin (373) 373
antineoplastic combined chemotherapy protocols - adverse effects (370) 370
deoxycytidine - analogs & derivatives (367) 367
paclitaxel (365) 365
carcinoma, non-small-cell lung - mortality (358) 358
survival (358) 358
aged, 80 and over (356) 356
trial (337) 337
deoxycytidine - administration & dosage (319) 319
survival rate (319) 319
survival analysis (292) 292
prognosis (290) 290
adjuvant chemotherapy (284) 284
care and treatment (263) 263
randomized-trial (259) 259
disease-free survival (232) 232
antineoplastic agents - therapeutic use (228) 228
chemotherapy, adjuvant (227) 227
pharmacology & pharmacy (221) 221
research (217) 217
carcinoma (213) 213
hematology, oncology and palliative medicine (213) 213
phase-iii trial (213) 213
non-small-cell lung cancer (212) 212
retrospective studies (202) 202
medicine & public health (199) 199
nsclc (199) 199
therapy (199) 199
combination (198) 198
lung neoplasms - surgery (196) 196
drug administration schedule (195) 195
surgery (195) 195
carboplatin - administration & dosage (191) 191
paclitaxel - administration & dosage (186) 186
carcinoma, non-small-cell lung - surgery (176) 176
phase-ii trial (172) 172
metaanalysis (171) 171
antineoplastic combined chemotherapy protocols - administration & dosage (168) 168
vinblastine - adverse effects (165) 165
clinical trials (155) 155
cell lung-cancer (153) 153
taxoids - administration & dosage (153) 153
radiotherapy (152) 152
phase-ii (149) 149
phase-iii (149) 149
pulmonary/respiratory (149) 149
quality-of-life (149) 149
combined modality therapy (142) 142
clinical-trials (140) 140
follow-up studies (139) 139
lung neoplasms - therapy (138) 138
cisplatin - adverse effects (129) 129
combination chemotherapy (126) 126
randomized trial (125) 125
deoxycytidine - adverse effects (124) 124
carcinoma, non-small-cell lung - therapy (123) 123
disease progression (122) 122
dose-response relationship, drug (122) 122
analysis (121) 121
lung neoplasms - genetics (121) 121
randomized controlled trials as topic (121) 121
breast neoplasms - drug therapy (120) 120
metastasis (119) 119
plus cisplatin (119) 119
supportive care (119) 119
elderly-patients (118) 118
drug therapy (116) 116
antineoplastic agents (115) 115
vinblastine - therapeutic use (115) 115
clinical trials as topic (114) 114
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1946) 1946
French (27) 27
German (9) 9
Spanish (6) 6
Chinese (3) 3
Japanese (2) 2
Portuguese (2) 2
Icelandic (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10054, pp. 1883 - 1892
Journal Article
The Lancet Oncology, ISSN 1470-2045, 01/2018, Volume 19, Issue 1, pp. 139 - 148
Cisplatin-based adjuvant chemotherapy is the standard of care for patients with resected stage II–IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT... 
CELL LUNG-CANCER | SURVIVAL | FORTHCOMING 7TH EDITION | 1ST-LINE TREATMENT | PLACEBO | ESMO CONSENSUS CONFERENCE | THERAPY | ONCOLOGY | TNM CLASSIFICATION | ERLOTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Pneumonectomy | Protein Kinase Inhibitors - adverse effects | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Young Adult | Time Factors | Vinblastine - analogs & derivatives | Vinblastine - adverse effects | China | Adult | Female | Quinazolines - administration & dosage | Chemotherapy, Adjuvant | Gefitinib | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Risk Factors | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Quinazolines - adverse effects | Cisplatin - adverse effects | Aged | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging | Vinorelbine | Lung cancer, Non-small cell | Care and treatment
Journal Article
Annals of Oncology, ISSN 0923-7534, 02/2007, Volume 18, Issue 2, pp. 317 - 323
Journal Article
Annals of Oncology, ISSN 0923-7534, 2/2008, Volume 19, Issue 2, pp. 362 - 369
Background: The Lung Cancer Cetuximab Study is an open-label, randomized phase II pilot study of cisplatin and vinorelbine combined with the epidermal growth... 
First-line | NSCLC | Cetuximab | Cisplatin | Epidermal growth factor receptor | Vinorelbine | CARBOPLATIN | GEFITINIB | epidermal growth factor receptor | cetuximab | CHEMOTHERAPY | GEMCITABINE | PACLITAXEL | vinorelbine | TRIAL | ONCOLOGY | FACTOR RECEPTOR MUTATIONS | first-line | EPIDERMAL-GROWTH-FACTOR | cisplatin | PREVIOUSLY TREATED PATIENTS | Lung Neoplasms - drug therapy | Confidence Intervals | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Reference Values | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized | Vinblastine - analogs & derivatives | Neoplasm Invasiveness - pathology | Vinblastine - adverse effects | Adult | Female | Carcinoma, Non-Small-Cell Lung - pathology | Drug Administration Schedule | Risk Assessment | Probability | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Maximum Tolerated Dose | Antibodies, Monoclonal - administration & dosage | Survival Analysis | Cisplatin - adverse effects | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging
Journal Article
Journal Article
British Journal of Cancer, ISSN 0007-0920, 09/2018, Volume 119, Issue 6, pp. 675 - 682
Journal Article
Journal Article
Lung Cancer, ISSN 0169-5002, 2014, Volume 83, Issue 3, pp. 363 - 368
Journal Article
The Lancet Respiratory Medicine, ISSN 2213-2600, 11/2018, Volume 6, Issue 11, pp. 863 - 873
Journal Article
Journal Article
Journal Article
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2009, Volume 45, Issue 13, pp. 2298 - 2303
Abstract Background In a large phase III study, cisplatin and pemetrexed had non-inferior efficacy and better tolerability compared with cisplatin and... 
Hematology, Oncology and Palliative Medicine | Gemcitabine | NSCLC | Toxicity | Histology | Pemetrexed | Survival | Cisplatin | 1ST-LINE TREATMENT | CARBOPLATIN | MULTICENTER | VINORELBINE | COMBINATION | DOCETAXEL | REGIMENS | CHEMOTHERAPY | PACLITAXEL | TRIAL | ONCOLOGY | Index Medicus
Journal Article